Robert A Baiocchi, MD, PhD

Robert Baiocchi

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Assoc Professor

Research Program

Leukemia Research

Research Interest

Cancer ● Lymphoma, Mantle-Cell ● Lymphoma ● Lymphoproliferative Disorders ● Lymphoma, Non-Hodgkin ● Leukemia, Lymphocytic, Chronic, B-Cell ● Lymphoma, B-Cell ● Burkitt Lymphoma

Robert Baiocchi, MD, PhD, is a member of the Leukemia Research Program at the OSUCCC – James and the associate director for Translational and Clinical Science in the Division of Hematology. His laboratory focuses on three major areas: (1) epigenetics of B-cell transformation, (2) experimental therapeutics of cancer and (3) immune surveillance of EBV-associated disease. He has over 20 years of experience investigating the pathogenesis of EBV-driven diseases and experimental therapeutics of lymphoma. Current work relevant to EBV-associated cancers includes strategies to develop an EBV vaccine for prevention of EBV-associated disorders in solid organ transplant patients and HIV/AIDS patients; experimental therapeutic strategies to specifically target herpes virus-associated malignancies; and the characterization of immune reconstitution in HIV-positive patients following autologous and allogeneic stem cell transplantation.

Dr. Baiocchi’s laboratory program investigating novel approaches to treat patients with mantle cell lymphoma is supported by a Leukemia Lymphoma Society Specialized Center of Research (SCOR) and NIH/NCI programmatic research grant (P01) in collaboration with Weil Cornell Medicine. He actively collaborates with both local and national investigators on basic, translational and clinical research projects. His translational research laboratory program has expertise in molecular genetics/virology, epigenetics and cellular biology techniques, molecular and cellular immunology, preclinical animal models for human malignancy, and the development of novel experimental therapeutic approaches to treat cancer. He has worked with The Ohio State University Drug Development Institute (DDI) and industry partners to translate several novel strategies to prevent and treat cancer from the lab into phase I clinical trials. His laboratory is fully funded by the NIH/NCI, ACS, QNRF and the Leukemia Lymphoma Society.

Since his arrival at Ohio State University, Dr. Baiocchi's efforts to commercialize and rapidly translate his team’s discoveries have led to the filing of more than ten patent applications. The intellectual property topics range from strategies to prevent EBV-driven cancers with a first-in-class vaccine to the discovery of a novel, first-in-class inhibitor of the PRMT5 enzyme to treat solid and hematologic malignancies. Both of these strategies were supported by Pelotonia funding early on in the form of Idea Grants and later with the support of the DDI. Dr. Baiocchi’s work with the EBV vaccine is currently being translated into the clinic with a pharmaceutical partner with plans for filing an Investigational New Drug (IND) application with the FDA in 2019. Work developing the PRMT5 inhibitor drug was licensed to a pharmaceutical partner with the help of OSU DDI and the Leukemia Lymphoma Society. The lead drug has been approved by the FDA for IND status and a phase I clinical trial is due to open in early 2019.

Dr. Baiocchi has written or co-written more than 60 articles that have been published in academic journals, including Cancer, Cancer Research, Journal of Biological Chemistry, Leukemia Research and American Journal of Hematology. In addition, he has made hundreds of presentations to organizations ranging from the International Association for Comparative Research on Leukemia and Related Diseases to Columbus-area school children on behalf of the Leukemia & Lymphoma Society.

He is a member of the Blood and Marrow Transplant Clinical Trials Network and an editorial board member for the journal BioMed Research International.


Education

  • MD, The Ohio State University

    Columbus, OH (USA)

  • Fellowship, The Ohio State University College of Medicine

    Columbus, OH (USA)

Residencies

  • Internship and Residency Internal Medicine

    ABIM Research Pathway

    Columbus, OH (USA)

  • Postdoctoral Fellow, Hematology and Oncology

    Roswell Park Cancer Institute Department of Medicine

    Buffalo, NY (USA)

Fellowship

  • Fellowhsip Medical Oncology

    The Ohio State University College of Medicine

    Columbus, OH (USA)

Office Location

B404 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210


6146-855-6667

614-292-3312



Publications

Back to Researcher Search

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Search for Clinical Trials

Find a Scientific Publication